| Followers | 1130 |
| Posts | 32805 |
| Boards Moderated | 3 |
| Alias Born | 01/11/2016 |
Monday, April 13, 2026 1:05:36 PM
If you don't understand the science, you shouldn't be investing in this at all. This science is going to spin heads, once the data is released, Brain Cancer treatment in Pediatrics is priceless. Easy triple dollars in the making.
Recent PSTV News
- Form 8-K - Current report • Edgar (US Regulatory) • 05/15/2026 08:46:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/15/2026 08:33:28 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/15/2026 08:13:11 PM
- Plus Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update on REYOBIQ™ Clinical Program and CNSide® Commercial Rollout • GlobeNewswire Inc. • 05/15/2026 08:05:00 PM
- Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 05/15/2026 04:21:08 PM
- Plus Therapeutics Announces Oral Presentation Highlighting REYOBIQ™ Clinical and Translational Data Demonstrating Favorable Safety, Survival, and Emerging Immunomodulation in Leptomeningeal Metastases • GlobeNewswire Inc. • 05/08/2026 11:30:00 AM
- Plus Therapeutics Receives Medicare Enrollment Approval for CNSide Diagnostic • GlobeNewswire Inc. • 05/07/2026 11:30:00 AM
- Plus Therapeutics Secures Blue Shield of California Coverage for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer • GlobeNewswire Inc. • 04/28/2026 11:30:00 AM
- Plus Therapeutics Initiates Manufacturing Activities with SpectronRx Under a Master Services Agreement to Support GMP Pivotal Trial Readiness for REYOBIQ™ • GlobeNewswire Inc. • 04/23/2026 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/22/2026 09:00:04 PM
- Plus Therapeutics Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 04/22/2026 08:30:00 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 04/21/2026 09:00:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/21/2026 12:30:16 PM
- Plus Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement • GlobeNewswire Inc. • 04/21/2026 11:30:00 AM
- Plus Therapeutics Appoints Randy H. Goodman, PhD, MHA, as Vice President of Value Strategy & HEOR to Advance Market Access and Commercial Execution • GlobeNewswire Inc. • 04/15/2026 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/09/2026 12:01:12 PM
- Plus Therapeutics Appoints Eric J. Daniels, M.D., MBA, as Chief Development Officer to Advance Clinical Pipeline • GlobeNewswire Inc. • 04/09/2026 11:30:00 AM
- Plus Therapeutics secures FDA orphan drug status for pediatric glioma treatment • IH Market News • 04/08/2026 02:00:51 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/08/2026 11:30:07 AM
- Plus Therapeutics Granted U.S. FDA Orphan Drug Designation to REYOBIQ™ in Pediatric Malignant Gliomas • GlobeNewswire Inc. • 04/08/2026 11:30:00 AM
- Plus Therapeutics Receives AMA PLA Code for CNSide® CSF Tumor Cell Enumeration Test, Advancing Reimbursement and U.S. Commercial Adoption • GlobeNewswire Inc. • 04/07/2026 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/02/2026 08:30:12 PM
- Plus Therapeutics Secures Highmark Coverage for CNSide® CSF Assay, Expanding Reimbursement to ~75 Million Covered Lives • GlobeNewswire Inc. • 04/02/2026 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/01/2026 11:30:05 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/01/2026 11:30:03 AM
